{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-26-000002","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.462349+00:00","generated_at":"2026-05-16T01:02:15.854367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track","bullets":["Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).","Q4 GAAP net loss of $47M vs $125M income prior year; Non-GAAP income $89M vs $180M.","ROCTAVIAN withdrawal triggered ~$240M Q4 charges ($119M inventory write-off, $118M asset impairments).","VOXZOGO FY revenue $927M (+26% Y/Y); PALYNZIQ $433M (+22% Y/Y).","2026 guidance provided (ex-Amicus); Amicus acquisition expected to close in Q2'26."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-26-000002","json":"https://secwatch.observer/filing/0001048477-26-000002.json","markdown":"https://secwatch.observer/filing/0001048477-26-000002.md","text":"https://secwatch.observer/filing/0001048477-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/0001048477-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/bmrn-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:02:15.854367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}